Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Graft vs Host Disease 4Myeloproliferative Disorders 3Myasthenia Gravis 3Lymphoma, Non-Hodgkin 3Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Skin Neoplasms 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Myeloproliferative Syndrome, Transient 1Multiple Myeloma 1Leukemia 1Congenital Abnormalities 1Chromosome 5q Deletion Syndrome 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

rozanolixizumab 7zilucoplan 6efgartigimod alfa 5eculizumab 4telitacicept 3ravulizumab 3Tacrolimus 3Rituximab 3Amifampridine 3Prednisone 2Mycophenolic Acid 2HBM9161 2satralizumab 1remibrutinib 1iptacopan 1inebilizumab 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisolone 1Plasmapheresis 1Leflunomide 1Immunoglobulins, Intravenous 1Hizentra 1Cladribine 1Azathioprine 1Alkalies 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Myasthenia Gravis × Tacrolimus × Clear all
NCT01325571 2016-03-09

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

Astellas Pharma Inc

Phase 3 Completed
83 enrolled

Myasthenia Gravis

NCT00309088 2014-08-25

FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients

Astellas Pharma Inc

Phase 3 Completed
80 enrolled

Myasthenia Gravis

NCT00309101 2009-06-03

An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

Astellas Pharma Inc

Phase 3 Completed
11 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡